MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

GlaxoSmithKline plc Company Profile (NYSE:GSK)

Consensus Ratings for GlaxoSmithKline plc (NYSE:GSK) (?)
Ratings Breakdown: 6 Sell Rating(s), 10 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Hold (Score: 2.04)
Consensus Price Target: $47.00 (8.02% upside)

Current Analysts' Coverage Summary for GlaxoSmithKline plc (NYSE:GSK)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2015Sanford C. BernsteinLower Price Target$43.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2015Liberum CapitalUpgradeSell -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015HSBCInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2015Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015JPMorgan Chase & Co.Reiterated RatingUnderweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015BNP ParibasReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2015Credit SuisseReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2015Berenberg BankReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Bank of AmericaReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Citigroup Inc.Initiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Societe GeneraleReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Deutsche BankReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Beaufort SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015BarclaysReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015Kepler Capital MarketsReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015Shore CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2015ArgusLower Price TargetBuy$55.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Panmure GordonReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2015S&P Equity ResearchDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2015New Street ResearchDowngradeReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/19/2014KillikReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2014Galvan ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2014Main First Bank AGDowngradeUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2014Cowen and CompanyDowngradeOutperform -> Market Perform$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2013MacquarieUpgradeNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/4/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha